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INTRODUCTION
Germ cell tumors are derived from the primordial germ
cells of the ovary and 20-25% of all benign and malignant
ovarian neoplasms are of germ cell origin (1). Vast majority
of these tumors are mature teratomas. 
Teratomas are composed of various tissues including hair,
skin, bone, teeth, as well as thyroid. Struma ovarii is a rare
monodermal variant of ovarian teratoma accounting for only
2% of all mature teratomas. To be classified as a struma ovarii,
teratoma must be composed predominantly of mature thy-
roid tissue (>50%) (2, 3). It is a benign condition, but occa-
sionally malignant transformation is observed in about 5%
of cases (4-6). Due to its rarity, there has been controversy
about the diagnosis and treatment. 
We report a case of malignant struma ovarii with a focus
of papillary thyroid cancer. 
CASE REPORT
A 40-yr-old, multiparous woman was admitted to the
Department of Gynaecology at Kocaeli University with the
complaint of pelvic pain for 2 yr. Her past medical history
was uneventful.
Her gynecological examination revealed a large pelvic mass
in the mid-portion of lower abdomen. Abdominal ultrasonog-
raphy showed a right hypoechoic mass measuring 15×20
cm suggestive of an ovarian neoplasm and a totally enlarged
uteri measuring 10×6×5 cm with multiple small-sized
myomas (0.5-2 cm) within the myometrium. Tumor mark-
ers and routine biochemistry were unremarkable. She was
performed total abdominal hysterectomy and right salpin-
go-oopherectomy. Macroscopically, the right ovary was rub-
bery in consistency, and on a cut section it was homogeneous
brown-tan in colour with areas of hemorrhage. An intraoper-
ative frozen section was reported as a benign cystic teratoma
containing thyroid tissue. Permanent sections of further sam-
pled tumor revealed a focus of papillary thyroid carcinoma
measuring 1 cm in diameter within the struma ovarii (Figs.
1-3). The tumor was totally confined within the teratomatous
thyroid tissue. The diagnosis was rendered using the histo-
pathological criteria similar to the guidelines for primary thy-
roid gland disease. Left salpingo-oopherectomy and retro-
peritoneal pelvic lympadenectomy were performed afterwards
for re-staging operation. Left ovary and lymph nodes were
histopathologically normal.
Her postoperative course was uneventful. After the opera-
tion, thyroid function tests and the thyroglobulin level were
evaluated. Thyroid stimulating hormone was suppressed and
free levels of thyroid hormones and thyroglobulin were in
normal ranges. She was offered thyroidectomy for the pur-
pose of confirmation of disease but the patient did not accept
the offer.
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Malignant Struma Ovarii: A Case Report
We present a case of a 40-yr-old woman diagnosed with a primary malignant stru-
ma ovarii. The patient was admitted with the complaint of pelvic pain and a large
pelvic mass in the mid-portion of lower abdomen on gynecological examination. Pre-
operative tumor markers and routine biochemistry were unremarkable. She was
treated with total abdominal hysterectomy and right salpingo-oopherectomy. Post-
operatively, she was diagnosed with a malignant struma ovarii through the usage
of histopathological criteria similar to the guidelines for primary thyroid gland disease.
The patient was subsequently performed left salpingo-oopherectomy and retroperi-
toneal pelvic lympadenectomy for re-staging. Although, left ovary and lymph nodes
were histopathologically normal, she was offered thyroidectomy but she refused to
accept the offer. Thyroglobulin level was monitored in the post-operative period. She
is free of the disease for 18 months.       
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ulin levels are within normal limits. Thyroid ultrasound scan-
ning is normal. 
DISCUSSION
Malignant struma ovarii is a rare gynecologic cancer. It may
occur at any age, but the peak frequence is in the fifth and
sixth decades of life. Rates of benign and malignant struma
ovarii among teratomas are 2 and 0.3%, respectively (4, 8).
The most common presenting symptom is a pelvic mass.
Eventhough it is a neoplasm consisting of thyroid tissue, only
8% of patients with struma ovarii present with clinical hyper-
thyroidism (7).
There are difficulties in the clinical diagnosis because of
the absence of uniform diagnostic criteria with the rarity of
the disease. The criterion for histopathological diagnosis has
varied over years. Lately, Devaney et al. (9) have advocated
that pathological diagnosis of malignant struma ovarii should
follow the same guidelines as those for thyroid carcinomas. 
Metastasis is rare in patients with malignant struma ovarii
(5%). Routes of metastasis described in the literature are: 1)
regional lymphatics to pelvic and paraaortic lymph nodes;
2) direct spread to the omentum and peritoneal cavity, the
contralateral cavity; and 3) hematologic dissemination to
the bone, lung, liver and brain (4, 10). These authors have
also proposed that struma ovarii with metastatic behavior
should be regarded as malignant (10, 11).
The optimum treatment of malignant struma ovarii is con-
traversial. Management alternatives include radical surgery
with or without thyroidectomy, followed by adjuvant thera-
py (external radiotherapy, chemotherapy, thyroid supression)
(12). Our opinion is that malignant struma ovarii should be
treated with combination surgery including total abdomi-
nal hysterectomy, bilateral salpingo-oopherectomy, pelvic-
paraaortic lymph node sampling and thyroidectomy followed
by I131 therapy. Thyroidectomy should be a part of radical
surgery due to two reasons: firstly we can exclude the possi-
bility of a primary thyroid carcinoma. Secondly after thyroidec-
tomy, we can recognize the metastasis, recurrence and resid-
ual tissue with total body scanning with I131 and serum thy-
roglobulin levels. Management of the patients who desire
fertility might be challenging. We agree with Dardik et al.
(7) in the way that they should be performed fertility spar-
ing surgery and definitive surgery after completion of child-
bearing. The patient was informed about the post-operative
follow-up procedures, but we were unable to convince the
patient about the thyroidectomy operation. Patients treated
without thyroidectomy with survival rates of 12 to 180 months
have been reported in the literature (11). As we are unable to
determine the metastasis, recurrence or the residual tissue
without thyroidectomy, we think that thyroidectomy should
be a part of treatment. 
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Fig. 1. Non encapsulated small papillary carcinoma within the thy-
roid tissue (H&E, ×40).
Fig. 2. On left side papillary tumor with typical nuclear features
contrasting the normal thyroid follicular epithelium (H&E, ×100).
Fig. 3. High power view of papillary carcinoma with enlarged, oval,
overlapping, ground glass nuclei (H&E, ×200).Serum thyroglobulin levels and I131 scan could be used
for the follow-up as a marker of recurrence (6, 13). If thy-
roidectomy is not performed, then I131 scan or thyroglobu-
lin have no aid in the follow-up (14). But cases in the litera-
ture similar to ours, have been reported, where follow-up has
been with thyroglobulin levels or no further examination or
where after fine-needle aspiration of thyroid chemotherapy
has been given (11, 12, 15). 
As malignant struma ovarii cases are rare, there is no stan-
dart follow-up protocol for patients who have not been per-
formed thyroidectomy.
In conclusion, more data is needed to determine an optimal
diagnosis, management and follow-up protocols for this rare
entity.
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